Ronald Lauder

Alzheimer's Drug Discovery Foundation (ADDF) Investment Boosts Search for Digital Biomarkers for Early Alzheimer's

Retrieved on: 
Monday, July 26, 2021

The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.

Key Points: 
  • The Diagnostics Accelerator provides funding to fast-track the development of affordable and accessible diagnostic tools and biomarkers for Alzheimer's disease and related dementias.
  • Recent research shows that Alzheimer'salso causes subtle early changes in aspects of behaviour such as sleep, speech, interactions, and movement.
  • While undetectable to the human eye, these changes can now be picked up by commercially available digital technologies.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Foundation For a Better World Honors Alzheimer's Drug Discovery Foundation with Inaugural Claugus Award

Retrieved on: 
Thursday, May 13, 2021

b'NEW YORK, May 13, 2021 /PRNewswire/ -- The Foundation For a Better World (FFBW) recently honored the Alzheimer\'s Drug Discovery Foundation (ADDF) with the inaugural Claugus Award for its commitment and dedication to Alzheimer\'s research.

Key Points: 
  • b'NEW YORK, May 13, 2021 /PRNewswire/ -- The Foundation For a Better World (FFBW) recently honored the Alzheimer\'s Drug Discovery Foundation (ADDF) with the inaugural Claugus Award for its commitment and dedication to Alzheimer\'s research.
  • "It was very important to me to honor my roots when it came to creating this award," she explained.
  • "The sculpture is an interpretation of a microscope, constructed from three intertwined glass elements representing the FFBW, the ADDF and the award, all of which work together to make the world a better place.
  • "\nFounded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer\'s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer\'s disease.

Alzheimer's Drug Discovery Foundation Appoints Christopher Johnson Co-Chair of Board of Overseers

Retrieved on: 
Friday, February 26, 2021

NEW YORK, Feb. 26, 2021 /PRNewswire/ --The Alzheimer's Drug Discovery Foundation (ADDF), a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announces that Christopher Johnson, CEO of Rackson Restaurants, has been appointed as Co-Chair of the ADDF's Board of Overseers .

Key Points: 
  • NEW YORK, Feb. 26, 2021 /PRNewswire/ --The Alzheimer's Drug Discovery Foundation (ADDF), a leading nonprofit solely focused on accelerating the development of drugs for Alzheimer's disease and related dementias, announces that Christopher Johnson, CEO of Rackson Restaurants, has been appointed as Co-Chair of the ADDF's Board of Overseers .
  • In this board leadership role, he will serve with co-chair Sharon Sager, Managing Director and Private Wealth Advisor at UBS Private Wealth Management.
  • "It's an honor to be given the opportunity to co-chair the board of such a forward-thinking organization," said Johnson.
  • Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Alzheimer's Drug Discovery Foundation (ADDF) Announces New Biobank Sharing Program to Accelerate Alzheimer's Disease Biomarker Research

Retrieved on: 
Wednesday, July 22, 2020

The clinical specimens provided through these agreements were collected under informed consent in past clinical trials to allow use of those samples for research purposes.

Key Points: 
  • The clinical specimens provided through these agreements were collected under informed consent in past clinical trials to allow use of those samples for research purposes.
  • Specimens are from trials that included patients at different stages of Alzheimer's disease and will be available to researchers developing cutting-edge biomarkers for diagnosis of Alzheimer's.
  • With these awards, the DxA has now invested nearly $16 million in 19 research projects around the world in both academic and biotech settings.
  • Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Vaccinex Announces $3 Million Award from the Alzheimer’s Drug Discovery Foundation

Retrieved on: 
Tuesday, December 10, 2019

The mission of the ADDF is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Key Points: 
  • The mission of the ADDF is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease.
  • This is the second award from a major Alzheimers research foundation to be announced recently in support of this study in Alzheimers disease, said Maurice Zauderer, President & CEO, Vaccinex, Inc. Last month, we announced a $750,000 grant from the Alzheimers Association for this same program.
  • Recently, it has been reported that FDG-PET is superior to A amyloid-PET as an indicator of cognitive decline in early Alzheimers disease.
  • Founded in 1998 by Leonard A. Lauder andRonald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

Alzheimer's Drug Discovery Foundation's Diagnostics Accelerator Announces Second Round of Awards

Retrieved on: 
Wednesday, December 4, 2019

NEW YORK, Dec. 4, 2019 /PRNewswire/ --The Alzheimer's Drug Discovery Foundation (ADDF) announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.

Key Points: 
  • NEW YORK, Dec. 4, 2019 /PRNewswire/ --The Alzheimer's Drug Discovery Foundation (ADDF) announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.
  • Excess amounts of these proteins aggregate to form amyloid plaques, one of the hallmark pathological signs of Alzheimer's disease.
  • This blood test is one of the most advanced blood tests in development for the diagnosis for Alzheimer's disease.
  • Founded in 1998 by Leonard A. Lauder andRonald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

DiamiR Receives Award from Alzheimer's Drug Discovery Foundation to Accelerate Development of microRNA Biomarkers for Alzheimer's Disease

Retrieved on: 
Wednesday, November 20, 2019

The award will accelerate the development of DiamiR's targeted diagnostic technology for detection and prediction of Alzheimer's disease (AD) progression.

Key Points: 
  • The award will accelerate the development of DiamiR's targeted diagnostic technology for detection and prediction of Alzheimer's disease (AD) progression.
  • The award is provided by the Alzheimer'sDrug Discovery Foundation (ADDF) Diagnostics Accelerator, a fund set up in collaboration with Bill Gates and other philanthropic partners.
  • microRNAs are small non-coding regulatory RNA molecules, which modulate gene expression and whose levels often change in disease.
  • Founded in 1998 with support from Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease.

WJC honors former US Ambassador to UN Nikki Haley with prestigious Theodor Herzl Award

Retrieved on: 
Sunday, November 10, 2019

"Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.

Key Points: 
  • "Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.
  • In all that we did at the UN, our approach to Israel was tied together by one major idea.
  • Former US Secretary of State Henry Kissinger, WJC President Ronald S. Lauder, and former US Ambassador to the UN Nikki Haley.
  • The World Jewish Congress (WJC) is the international organization representing Jewish communities in 100 countries to governments, parliaments and international organizations.

WJC honors former US Ambassador to UN Nikki Haley with prestigious Theodor Herzl Award

Retrieved on: 
Friday, November 8, 2019

"Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.

Key Points: 
  • "Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.
  • In all that we did at the UN, our approach to Israel was tied together by one major idea.
  • Former US Secretary of State Henry Kissinger, WJC President Ronald S. Lauder, and former US Ambassador to the UN Nikki Haley.
  • The World Jewish Congress (WJC) is the international organization representing Jewish communities in 100 countries to governments, parliaments and international organizations.

WJC honors former US Ambassador to UN Nikki Haley with prestigious Theodor Herzl Award

Retrieved on: 
Friday, November 8, 2019

"Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.

Key Points: 
  • "Some people accused us of favoritism toward Israel," Haley related, adding: "But what we did was really not about favoritism.
  • In all that we did at the UN, our approach to Israel was tied together by one major idea.
  • Former US Secretary of State Henry Kissinger, WJC President Ronald S. Lauder, and former US Ambassador to the UN Nikki Haley.
  • The World Jewish Congress (WJC) is the international organization representing Jewish communities in 100 countries to governments, parliaments and international organizations.